Sales & Marketing Closed & Collaborative H1 2025: Mergers, acquisitions, colla... The first half of 2025 has been marked by a surge in strategic activity across the global healthcare, life sciences, and biotechnology sectors.
R&D Closed and Collaborative: Mergers, acquisitions, and partner... As we head further into H2, a final look back to the summer’s industry mergers and acquisiti
R&D Closed and Collaborative: Mergers, acquisitions, and partner... Summer’s stretch having drawn out a longer return to our round-ups, as the days shorten and we firmly enter autumn, pharmaphorum takes a look back at the industry
R&D Closed and Collaborative: Mergers, acquisitions, and partner... Welcome to a new pharmaphorum round-up.
Market Access A year of major M&A ahead? The previous few years have seen a slowdown in M&A across the industry, as companies take a cautious approach to expansion.
News Chiesi expands rare disease portfolio with Amryt Pharma acqu... Biopharma and healthcare group Chiesi Farmaceutici S.p.A.
Oncology ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C... At ASCO 2026, BI Global Head of Oncology Itziar Canamasas spoke with pharmaphorum about the company's ASCO data and broader oncology strategy.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.